Lurasidone is an atypical antipsychotic for the treatment of: 

• Schizophrenia
• Depressive Episodes associated with Bipolar Disorder (bipolar depression) as monotherapy and as adjunctive therapy with lithium or valproate 

Schizophrenia

Bipolar Disorder

Schizophrenia

• Starting dose: 40 mg per day
• Recommended Dose: 40 to 160 mg per day 

Bipolar Depression

• Starting dose: 20 mg per day
• Recommended Dose: 20 to 120 mg per day 

• Schizophrenia: somnolence, akathisia, extrapyramidal symptoms, and nausea
• Bipolar depression: akathisia, extrapyramidal symptoms, and somnolence

Somnolence

Tremor (Shaking)

Nausea

• Cerebrovascular Adverse Reactions in Elderly Patients with Dementia-Related Psychosis: Increased incidence of cerebrovascular adverse events (e.g., stroke, transient ischemic attack)
• Neuroleptic Malignant Syndrome: Manage with immediate discontinuation and close monitoring
• Tardive Dyskinesia: Discontinue if clinically appropriate
• Metabolic Changes:  Atypical antipsychotic drugs have been associated with metabolic changes that may increase cardiovascular/cerebrovascular risk. These metabolic changes include hyperglycemia, dyslipidemia, and weight gain
• Hyperglycemia and Diabetes Mellitus: Monitor patients for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness. Monitor glucose regularly in patients with diabetes or at risk for diabetes.
• Dyslipidemia: Undesirable alterations have been observed in patients treated with atypical antipsychotics.
• Weight Gain: Gain in body weight has been observed. Monitor weight.
• Hyperprolactinemia: Prolactin elevations may occur
• Leukopenia, Neutropenia, and Agranulocytosis:  Perform complete blood counts (CBC) in patients with a pre-existing low white blood cell count (WBC) or a history of leukopenia or neutropenia. Consider discontinuing Lurasidone Hydrochloride if a clinically significant decline in WBC occurs in the absence of other causative factors 
• Orthostatic Hypotension and Syncope: Dizziness, tachycardia or bradycardia, and syncope may occur, especially early in treatment. In patients with known cardiovascular or cerebrovascular disease, and in antipsychotic-naïve patients, consider a lower starting dose and slower titration